A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins

Stephen B. Keysar, David P. Astling, Ryan T. Anderson, Brian W. Vogler, Daniel W. Bowles, J. Jason Morton, Jeramiah J. Paylor, Magdalena J. Glogowska, Phuong N. Le, Justin R. Eagles-Soukup, Severine L. Kako, Sarah M. Takimoto, Daniel B. Sehrt, Adrian Umpierrez, Morgan A. Pittman, Sarah M. Macfadden, Ryan M. Helber, Scott Peterson, Diana F. Hausman, Sherif Said & 12 others Ted H. Leem, Julie A. Goddard, John J. Arcaroli, Wells A. Messersmith, William A. Robinson, Fred R. Hirsch, Marileila Varella-Garcia, David Raben, Xiao Jing Wang, John I. Song, Aik-Choon Tan, Antonio Jimeno

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Targeted therapy development in head and neck squamous cell carcinoma (HNSCC) is challenging given the rarity of activating mutations. Additionally, HNSCC incidence is increasing related to human papillomavirus (HPV). We sought to develop an invivo model derived from patients reflecting the evolving HNSCC epidemiologic landscape, and use it to identify new therapies. Primary and relapsed tumors from HNSCC patients, both HPV+ and HPV-, were implanted on mice, giving rise to 25 strains. Resulting xenografts were characterized by detecting key mutations, measuring protein expression by IHC and gene expression/pathway analysis by mRNA-sequencing. Drug efficacy studies were run with representative xenografts using the approved drug cetuximab as well as the new PI3K inhibitor PX-866. Tumors maintained their original morphology, genetic profiles and drug susceptibilities through serial passaging. The genetic makeup of these tumors was consistent with known frequencies of TP53, PI3KCA, NOTCH1 and NOTCH2 mutations. Because the EGFR inhibitor cetuximab is a standard HNSCC therapy, we tested its efficacy and observed a wide spectrum of efficacy. Cetuximab-resistant strains had higher PI3K/Akt pathway gene expression and protein activation than cetuximab-sensitive strains. The PI3K inhibitor PX-866 had anti-tumor efficacy in HNSCC models with PIK3CA alterations. Finally, PI3K inhibition was effective in two cases with NOTCH1 inactivating mutations. In summary, we have developed an HNSCC model covering its clinical spectrum whose major genetic alterations and susceptibility to anticancer agents represent contemporary HNSCC. This model enables to prospectively test therapeutic-oriented hypotheses leading to personalized medicine.

Original languageEnglish
Pages (from-to)776-790
Number of pages15
JournalMolecular Oncology
Volume7
Issue number4
DOIs
Publication statusPublished - 2013 Aug 1
Externally publishedYes

Fingerprint

Squamous Cell Neoplasms
Phosphatidylinositol 3-Kinases
Transplants
Neoplasms
Mutation
Therapeutics
Heterografts
Pharmaceutical Preparations
Gene Expression
Precision Medicine
Carcinoma, squamous cell of head and neck
Genetic Predisposition to Disease
Cell- and Tissue-Based Therapy
Antineoplastic Agents
Proteins
Messenger RNA
Cetuximab
Incidence

Keywords

  • EGFR
  • Head and neck cancer
  • Human papillomavirus
  • NOTCH1
  • PI3K
  • Xenografts

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Medicine

Cite this

Keysar, S. B., Astling, D. P., Anderson, R. T., Vogler, B. W., Bowles, D. W., Morton, J. J., ... Jimeno, A. (2013). A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Molecular Oncology, 7(4), 776-790. https://doi.org/10.1016/j.molonc.2013.03.004

A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. / Keysar, Stephen B.; Astling, David P.; Anderson, Ryan T.; Vogler, Brian W.; Bowles, Daniel W.; Morton, J. Jason; Paylor, Jeramiah J.; Glogowska, Magdalena J.; Le, Phuong N.; Eagles-Soukup, Justin R.; Kako, Severine L.; Takimoto, Sarah M.; Sehrt, Daniel B.; Umpierrez, Adrian; Pittman, Morgan A.; Macfadden, Sarah M.; Helber, Ryan M.; Peterson, Scott; Hausman, Diana F.; Said, Sherif; Leem, Ted H.; Goddard, Julie A.; Arcaroli, John J.; Messersmith, Wells A.; Robinson, William A.; Hirsch, Fred R.; Varella-Garcia, Marileila; Raben, David; Wang, Xiao Jing; Song, John I.; Tan, Aik-Choon; Jimeno, Antonio.

In: Molecular Oncology, Vol. 7, No. 4, 01.08.2013, p. 776-790.

Research output: Contribution to journalArticle

Keysar, SB, Astling, DP, Anderson, RT, Vogler, BW, Bowles, DW, Morton, JJ, Paylor, JJ, Glogowska, MJ, Le, PN, Eagles-Soukup, JR, Kako, SL, Takimoto, SM, Sehrt, DB, Umpierrez, A, Pittman, MA, Macfadden, SM, Helber, RM, Peterson, S, Hausman, DF, Said, S, Leem, TH, Goddard, JA, Arcaroli, JJ, Messersmith, WA, Robinson, WA, Hirsch, FR, Varella-Garcia, M, Raben, D, Wang, XJ, Song, JI, Tan, A-C & Jimeno, A 2013, 'A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins', Molecular Oncology, vol. 7, no. 4, pp. 776-790. https://doi.org/10.1016/j.molonc.2013.03.004
Keysar, Stephen B. ; Astling, David P. ; Anderson, Ryan T. ; Vogler, Brian W. ; Bowles, Daniel W. ; Morton, J. Jason ; Paylor, Jeramiah J. ; Glogowska, Magdalena J. ; Le, Phuong N. ; Eagles-Soukup, Justin R. ; Kako, Severine L. ; Takimoto, Sarah M. ; Sehrt, Daniel B. ; Umpierrez, Adrian ; Pittman, Morgan A. ; Macfadden, Sarah M. ; Helber, Ryan M. ; Peterson, Scott ; Hausman, Diana F. ; Said, Sherif ; Leem, Ted H. ; Goddard, Julie A. ; Arcaroli, John J. ; Messersmith, Wells A. ; Robinson, William A. ; Hirsch, Fred R. ; Varella-Garcia, Marileila ; Raben, David ; Wang, Xiao Jing ; Song, John I. ; Tan, Aik-Choon ; Jimeno, Antonio. / A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. In: Molecular Oncology. 2013 ; Vol. 7, No. 4. pp. 776-790.
@article{f0ffda010c5b4871839a4dcfd7bba3f6,
title = "A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins",
abstract = "Targeted therapy development in head and neck squamous cell carcinoma (HNSCC) is challenging given the rarity of activating mutations. Additionally, HNSCC incidence is increasing related to human papillomavirus (HPV). We sought to develop an invivo model derived from patients reflecting the evolving HNSCC epidemiologic landscape, and use it to identify new therapies. Primary and relapsed tumors from HNSCC patients, both HPV+ and HPV-, were implanted on mice, giving rise to 25 strains. Resulting xenografts were characterized by detecting key mutations, measuring protein expression by IHC and gene expression/pathway analysis by mRNA-sequencing. Drug efficacy studies were run with representative xenografts using the approved drug cetuximab as well as the new PI3K inhibitor PX-866. Tumors maintained their original morphology, genetic profiles and drug susceptibilities through serial passaging. The genetic makeup of these tumors was consistent with known frequencies of TP53, PI3KCA, NOTCH1 and NOTCH2 mutations. Because the EGFR inhibitor cetuximab is a standard HNSCC therapy, we tested its efficacy and observed a wide spectrum of efficacy. Cetuximab-resistant strains had higher PI3K/Akt pathway gene expression and protein activation than cetuximab-sensitive strains. The PI3K inhibitor PX-866 had anti-tumor efficacy in HNSCC models with PIK3CA alterations. Finally, PI3K inhibition was effective in two cases with NOTCH1 inactivating mutations. In summary, we have developed an HNSCC model covering its clinical spectrum whose major genetic alterations and susceptibility to anticancer agents represent contemporary HNSCC. This model enables to prospectively test therapeutic-oriented hypotheses leading to personalized medicine.",
keywords = "EGFR, Head and neck cancer, Human papillomavirus, NOTCH1, PI3K, Xenografts",
author = "Keysar, {Stephen B.} and Astling, {David P.} and Anderson, {Ryan T.} and Vogler, {Brian W.} and Bowles, {Daniel W.} and Morton, {J. Jason} and Paylor, {Jeramiah J.} and Glogowska, {Magdalena J.} and Le, {Phuong N.} and Eagles-Soukup, {Justin R.} and Kako, {Severine L.} and Takimoto, {Sarah M.} and Sehrt, {Daniel B.} and Adrian Umpierrez and Pittman, {Morgan A.} and Macfadden, {Sarah M.} and Helber, {Ryan M.} and Scott Peterson and Hausman, {Diana F.} and Sherif Said and Leem, {Ted H.} and Goddard, {Julie A.} and Arcaroli, {John J.} and Messersmith, {Wells A.} and Robinson, {William A.} and Hirsch, {Fred R.} and Marileila Varella-Garcia and David Raben and Wang, {Xiao Jing} and Song, {John I.} and Aik-Choon Tan and Antonio Jimeno",
year = "2013",
month = "8",
day = "1",
doi = "10.1016/j.molonc.2013.03.004",
language = "English",
volume = "7",
pages = "776--790",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins

AU - Keysar, Stephen B.

AU - Astling, David P.

AU - Anderson, Ryan T.

AU - Vogler, Brian W.

AU - Bowles, Daniel W.

AU - Morton, J. Jason

AU - Paylor, Jeramiah J.

AU - Glogowska, Magdalena J.

AU - Le, Phuong N.

AU - Eagles-Soukup, Justin R.

AU - Kako, Severine L.

AU - Takimoto, Sarah M.

AU - Sehrt, Daniel B.

AU - Umpierrez, Adrian

AU - Pittman, Morgan A.

AU - Macfadden, Sarah M.

AU - Helber, Ryan M.

AU - Peterson, Scott

AU - Hausman, Diana F.

AU - Said, Sherif

AU - Leem, Ted H.

AU - Goddard, Julie A.

AU - Arcaroli, John J.

AU - Messersmith, Wells A.

AU - Robinson, William A.

AU - Hirsch, Fred R.

AU - Varella-Garcia, Marileila

AU - Raben, David

AU - Wang, Xiao Jing

AU - Song, John I.

AU - Tan, Aik-Choon

AU - Jimeno, Antonio

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Targeted therapy development in head and neck squamous cell carcinoma (HNSCC) is challenging given the rarity of activating mutations. Additionally, HNSCC incidence is increasing related to human papillomavirus (HPV). We sought to develop an invivo model derived from patients reflecting the evolving HNSCC epidemiologic landscape, and use it to identify new therapies. Primary and relapsed tumors from HNSCC patients, both HPV+ and HPV-, were implanted on mice, giving rise to 25 strains. Resulting xenografts were characterized by detecting key mutations, measuring protein expression by IHC and gene expression/pathway analysis by mRNA-sequencing. Drug efficacy studies were run with representative xenografts using the approved drug cetuximab as well as the new PI3K inhibitor PX-866. Tumors maintained their original morphology, genetic profiles and drug susceptibilities through serial passaging. The genetic makeup of these tumors was consistent with known frequencies of TP53, PI3KCA, NOTCH1 and NOTCH2 mutations. Because the EGFR inhibitor cetuximab is a standard HNSCC therapy, we tested its efficacy and observed a wide spectrum of efficacy. Cetuximab-resistant strains had higher PI3K/Akt pathway gene expression and protein activation than cetuximab-sensitive strains. The PI3K inhibitor PX-866 had anti-tumor efficacy in HNSCC models with PIK3CA alterations. Finally, PI3K inhibition was effective in two cases with NOTCH1 inactivating mutations. In summary, we have developed an HNSCC model covering its clinical spectrum whose major genetic alterations and susceptibility to anticancer agents represent contemporary HNSCC. This model enables to prospectively test therapeutic-oriented hypotheses leading to personalized medicine.

AB - Targeted therapy development in head and neck squamous cell carcinoma (HNSCC) is challenging given the rarity of activating mutations. Additionally, HNSCC incidence is increasing related to human papillomavirus (HPV). We sought to develop an invivo model derived from patients reflecting the evolving HNSCC epidemiologic landscape, and use it to identify new therapies. Primary and relapsed tumors from HNSCC patients, both HPV+ and HPV-, were implanted on mice, giving rise to 25 strains. Resulting xenografts were characterized by detecting key mutations, measuring protein expression by IHC and gene expression/pathway analysis by mRNA-sequencing. Drug efficacy studies were run with representative xenografts using the approved drug cetuximab as well as the new PI3K inhibitor PX-866. Tumors maintained their original morphology, genetic profiles and drug susceptibilities through serial passaging. The genetic makeup of these tumors was consistent with known frequencies of TP53, PI3KCA, NOTCH1 and NOTCH2 mutations. Because the EGFR inhibitor cetuximab is a standard HNSCC therapy, we tested its efficacy and observed a wide spectrum of efficacy. Cetuximab-resistant strains had higher PI3K/Akt pathway gene expression and protein activation than cetuximab-sensitive strains. The PI3K inhibitor PX-866 had anti-tumor efficacy in HNSCC models with PIK3CA alterations. Finally, PI3K inhibition was effective in two cases with NOTCH1 inactivating mutations. In summary, we have developed an HNSCC model covering its clinical spectrum whose major genetic alterations and susceptibility to anticancer agents represent contemporary HNSCC. This model enables to prospectively test therapeutic-oriented hypotheses leading to personalized medicine.

KW - EGFR

KW - Head and neck cancer

KW - Human papillomavirus

KW - NOTCH1

KW - PI3K

KW - Xenografts

UR - http://www.scopus.com/inward/record.url?scp=84880721268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880721268&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2013.03.004

DO - 10.1016/j.molonc.2013.03.004

M3 - Article

VL - 7

SP - 776

EP - 790

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 4

ER -